News from bergenbio asa A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

15 Jan, 2020, 16:31 GMT BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda® in NSCLC Patients Progressing on Immune Checkpoint Inhibitors

BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


09 Dec, 2019, 06:35 GMT BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019

- Phase II trial evaluating bemcentinib in combination with low-dose cytarabine (LDAC) in elderly AML patients unfit for intensive therapy is well...


19 Nov, 2019, 06:25 GMT BerGenBio ASA: Results for the Third Quarter 2019

FDA granted Fast Track Designation for 2L Acute Myeloid Leukaemia (AML) High Impact oral presentation of 2L NSCLC clinical data at SITC Met primary...


08 Nov, 2019, 12:33 GMT BerGenBio Presents Updated Phase 2 NSCLC Clinical and Translational Data for Bemcentinib in Combination With KEYTRUDA®

- BerGenBio's proprietary Composite AXL Tumor-Immune Score predicts patients that have significantly prolonged clinical benefit - Primary endpoint of ...


07 Nov, 2019, 11:46 GMT BerGenBio to Present Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC Trial in Elderly AML Patients at ASH 2019

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


07 Nov, 2019, 06:35 GMT BerGenBio ASA: Invitation to Third Quarter 2019 Results Presentation and Webcast

BerGenBio ASA (OSE:BGBIO), will announce its results for the third quarter on Tuesday 19 November 2019. A presentation by BerGenBio's senior...


06 Nov, 2019, 06:47 GMT BerGenbio's Bemcentinib Meets Primary Endpoint in First Cohort of Phase 2 NSCLC Study in Combination With Keytruda®

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


22 Oct, 2019, 13:40 BST BerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


02 Oct, 2019, 06:14 BST BerGenBio to Present Clinical Data From Phase II Trial With Selective AXL Inhibitor at 34th Annual SITC Meeting

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


27 Sep, 2019, 11:31 BST BerGenBio Presents Phase II Trial Updates with Selective AXL Inhibitor Bemcentinib at the European Society for Medical Oncology (ESMO) 2019 Congress

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


09 Sep, 2019, 04:00 BST BerGenBio Presents Phase II Trial Updates With Selective AXL Inhibitor Bemcentinib in Non-Small Cell Lung Cancer at 2019 World Conference on Lung Cancer

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


19 Aug, 2019, 06:22 BST BerGenBio ASA: Results for the Second Quarter and First Half 2019

- Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly...


14 Jun, 2019, 11:40 BST BerGenBio Presents Preliminary Phase II Clinical Data at EHA 24: Bemcentinib in Combination With Low Dose Chemotherapy Yields Durable Responses in AML Patients Unfit for Intensive Chemotherapy

Two posters to be presented at the 2019 annual congress of the European Hematology Association on 14th June Phase II trial evaluating bemcentinib in...


03 Jun, 2019, 14:09 BST BerGenBio Presents New Phase II Clinical Data That Bemcentinib in Combination With Low Dose Chemotherapy Improves Efficacy and Duration of Survival in Elderly AML Patients at ASCO 2019

Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly AML patients unfit for intensive therapy shows...


02 Jun, 2019, 14:35 BST BerGenBio Presents New Preliminary Clinical and Biomarker Data Showing Durable Response & Median Survival Rates in Phase II Trial With Bemcentinib and KEYTRUDA in Pts With Advanced NSCLC at ASCO 2019

Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month survival data surpassing historical...


15 May, 2019, 23:35 BST BerGenBio to Present New NSCLC and AML Clinical Data and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019

Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at ASCO 2019 Non-Small-Cell Lung Cancer (NSCLC)...


08 May, 2019, 11:46 BST BerGenBio Completes Recruitment Into Second Stage of Phase II Trial With Selective AXL inhibitor bemcentinib in Combination with KEYTRUDA® in Patients With Advanced NSCLC

BerGenBio ASA (OSE: BGBIO) announces that it has completed enrolment into the second stage of its Phase II trial (BGBC008, Cohort A NCT03184571)...


08 May, 2019, 06:17 BST BerGenBio ASA: Results for the First Quarter 2019

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


24 Apr, 2019, 10:49 BST BerGenBio ASA: Invitation to First Quarter Presentation and Webcast

BerGenBio ASA (OSE:BGBIO), will announce its results for the first quarter on Wednesday, 8 May 2019. A presentation by BerGenBio's senior management...


23 Apr, 2019, 06:54 BST BerGenBio to Present NSCLC and AML Clinical Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019

BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


09 Apr, 2019, 06:32 BST BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting...


02 Apr, 2019, 10:26 BST BerGenBio Extends Phase II Trial With Bemcentinib and KEYTRUDA® in NSCLC to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy

BerGenBio ASA (OSE: BGBIO) announces that the first patient has been dosed in an additional cohort ("Cohort B") of an ongoing Phase II open-label...


02 Apr, 2019, 06:13 BST BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating AXL's role in reversing...


01 Apr, 2019, 11:22 BST BerGenBio: Bemcentinib in Combination With low-dose Chemotherapy Achieves Efficacy Endpoint in AML Patients

Phase II trial evaluating bemcentinib in combination with low-dose chemotherapy in AML patients unfit for intensive therapy Bemcentinib + low-dose...


20 Feb, 2019, 15:39 GMT BerGenBio ASA Publishes Annual Report for 2018

The Board of Directors of BerGenBio ASA (OSE: BGBIO) has today approved the Company's Annual Report for 2018 including the complete 2018 Annual...